CFLAR and prostate carcinoma: OH14 also sensitised tumour cells to docetaxel both in vitro and in vivo.<h4>Conclusions</h4>Inhibition of cFLIP in combination with either TRAIL or docetaxel has the potential to be used as a novel therapeutic approach to provide more potent, long-lasting benefits to men with prostate cancer.